Advertisement
Mabwell-b

Mabwell-b Fundamental Analysis

2493.HKHKSE
HealthcareBiotechnology
HK$22.78
HK$0.06(0.26%)
Hong Kong Market opens in 39h 31m
Advertisement

Mabwell-b Fundamental Analysis

Mabwell-b (2493.HK) shows weak financial fundamentals with a PE ratio of -8.62, profit margin of -1.23%, and ROE of -1.81%. The company generates $1.0B in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

Cash Position16.48%
PEG Ratio-0.52

Areas of Concern

ROE-1.81%
Operating Margin-1.18%
Current Ratio0.88
We analyze 2493.HK's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -338.3/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-338.3/100

We analyze 2493.HK's fundamental strength across five key dimensions:

Efficiency Score

Weak

2493.HK struggles to generate sufficient returns from assets.

ROA > 10%
-20.13%

Valuation Score

Excellent

2493.HK trades at attractive valuation levels.

PE < 25
-8.62
PEG Ratio < 2
-0.52

Growth Score

Weak

2493.HK faces weak or negative growth trends.

Revenue Growth > 5%
N/A
EPS Growth > 10%
N/A

Financial Health Score

Weak

2493.HK carries high financial risk with limited liquidity.

Debt/Equity < 1
27.03
Current Ratio > 1
0.88

Profitability Score

Weak

2493.HK struggles to sustain strong margins.

ROE > 15%
-180.70%
Net Margin ≥ 15%
-1.23%
Positive Free Cash Flow
No

Key Financial Metrics

Is 2493.HK Expensive or Cheap?

P/E Ratio

2493.HK trades at -8.62 times earnings. This suggests potential undervaluation.

-8.62

PEG Ratio

When adjusting for growth, 2493.HK's PEG of -0.52 indicates potential undervaluation.

-0.52

Price to Book

The market values Mabwell-b at 73.29 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

73.29

EV/EBITDA

Enterprise value stands at -12.77 times EBITDA. This is generally considered low.

-12.77

How Well Does 2493.HK Make Money?

Net Profit Margin

For every $100 in sales, Mabwell-b keeps $-1.23 as profit after all expenses.

-1.23%

Operating Margin

Core operations generate -1.18 in profit for every $100 in revenue, before interest and taxes.

-1.18%

ROE

Management delivers $-1.81 in profit for every $100 of shareholder equity.

-1.81%

ROA

Mabwell-b generates $-20.13 in profit for every $100 in assets, demonstrating efficient asset deployment.

-20.13%

Following the Money - Real Cash Generation

Operating Cash Flow

Mabwell-b generates limited operating cash flow of $-429.97M, signaling weaker underlying cash strength.

$-429.97M

Free Cash Flow

Mabwell-b generates weak or negative free cash flow of $-664.46M, restricting financial flexibility.

$-664.46M

FCF Per Share

Each share generates $-1.20 in free cash annually.

$-1.20

FCF Yield

2493.HK converts -4.33% of its market value into free cash.

-4.33%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-8.62

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.52

vs 25 benchmark

P/B Ratio

Price to book value ratio

73.29

vs 25 benchmark

P/S Ratio

Price to sales ratio

14.71

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

27.03

vs 25 benchmark

Current Ratio

Current assets to current liabilities

0.88

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-1.81

vs 25 benchmark

ROA

Return on assets percentage

-0.20

vs 25 benchmark

ROCE

Return on capital employed

-0.41

vs 25 benchmark

How 2493.HK Stacks Against Its Sector Peers

Metric2493.HK ValueSector AveragePerformance
P/E Ratio-8.6229.63 Better (Cheaper)
ROE-180.70%223.00% Weak
Net Margin-123.40%-38669.00% (disorted) Weak
Debt/Equity27.030.82 Weak (High Leverage)
Current Ratio0.884.30 Weak Liquidity
ROA-20.13%-379.00% (disorted) Weak

2493.HK outperforms its industry in 1 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Mabwell-b's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Fundamental Analysis FAQ